Latest Conference Articles

Adding CAN-2409 to standard radiation therapy significantly improved disease-free survival and pathological complete response rates in intermediate-to-high-risk prostate cancer.

Alicia Morgans, MD, MPH, discusses the phase 3 ARASTEP trial evaluating darolutamide in patients at high risk of biochemical recurrence of prostate cancer.

Ziftomenib shows promising results in treating relapsed/refractory NPM1-mutant AML, achieving significant remission rates and a favorable safety profile.

Neoadjuvant nivolumab plus chemotherapy significantly improves overall survival in resectable non-small cell lung cancer, marking a treatment breakthrough.

Vincent Picozzi, MD, discusses findings from the phase 3 trial PANOVA-3 of TTFields with gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer.

The ShorTrip trial found that short-course radiotherapy followed by FOLFOX and FOLFOXIRI improved pathological response rates in locally advanced rectal cancer.

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

The ongoing ARASTEP trial evaluates darolutamide plus ADT vs placebo for high-risk prostate cancer biochemical recurrence with PSMA PET-CT-positive lesions, aiming to improve rPFS.

Lifileucel therapy shows promising long-term survival and response rates in advanced melanoma patients, offering hope for those with limited treatment options.

Olaparib and radium-223 bested radium-223 alone in radiographic progression-free survival in men with castration-resistant prostate cancer.

Linda Duska, MD, FASCO, MPH, discusses the importance of the KEYNOTE-A18 study reinforcing the new standard of care of pembrolizumab plus concurrent chemoradiotherapy in locally advanced cervical cancer.

Meghan Mooradian, MD, discusses findings and implications of the phase 2 NEO-MEL-T study.

Darolutamide significantly delayed pain progression and improved overall well-being in patients with metastatic hormone-sensitive prostate cancer.

Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in high-risk locally advanced cervical cancer, establishing a new standard of care.

The FIRST/ENGOT-OV44 trial found dostarlimab plus platinum-chemo and niraparib maintenance modestly improved PFS (20.6 vs 19.2 months) in advanced ovarian cancer, with expected safety.

DeLLphi-304 trial results showed tarlatamab significantly improved PFS and OS over chemotherapy in second-line SCLC, establishing it as a new standard.

A prophylactic dermatologic regimen significantly reduced skin side effects and improved quality of life for NSCLC patients on amivantamab/lazertinib.

J. Randolph (Randy) Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

Benmelstobart alone or with anlotinib improved progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.

Atezolizumab plus cabozantinib or cabozantinib alone showed efficacy and manageable safety in second-line renal cell carcinoma.

The ALNEO trial's final analysis shows neoadjuvant alectinib is effective and well tolerated in resectable stage III ALK-positive NSCLC, achieving 42% MPR and 67% ORR, suggesting a feasible perioperative option.

Niraparib with AAP cut the risk of progression or death by 37% in HRR-altered mCSPC, according to data from the AMPLITUDE trial.

Helena Yu, MD, discusses the importance of zipalertinib's oral administration route for patients with EGFRm non–small cell lung cancer.

The first-line regimen of disitamab vedotin, toripalimab, and trastuzumab revealed superior efficacy and response rates vs disitamab vedotin, toripalimab, and chemotherapy in HER2-expressing locally advanced or metastatic G/GEJ cancer.

Helena Yu, MD, discusses the efficacy of zipalertinib for EGFR-mutant non–small cell lung cancer and the importance of exploring therapies with CNS penetration in this space.

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy in the space.